<DOC>
	<DOCNO>NCT00802438</DOCNO>
	<brief_summary>A drug ( mepolizumab ) reduce allergic inflammation affect function allergy cell call eosinophil produce body response allergen exposure .</brief_summary>
	<brief_title>Eosinophilic Airway Inflammation Mepolizumab</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<criteria>Males female age 18 50 yr , History asthma base upon presence asthma symptom cough , shortness breath , wheeze chest tightness , positive skinprick test House Dust Mite extract , Forced expiratory volume one second &gt; 70 % predict prealbuterol , &gt; 80 % predict post albuterol &gt; 12 % increase Forced expiratory volume one second follow inhale albuterol ( 180 Âµg ) and/or airway responsiveness methacholine ( PC20 &lt; 8mg/ml ) . &gt; 20 % immediate drop FEV1 follow inhaled antigen challenge . Safety laboratory assessment within normal range ( labs include complete blood count differential , blood urea nitrogen , creatinine , aspartate aminotransferase , alanine aminotransferase , Prothrombin time , Partial Thromboplastin Time , platelet count ) Female subject childbearing potential must negative urine pregnancy test ( urine HCG ) within 48 hour methacholine challenge Visit 2 agree use reliable method birth control duration study ( reliable method birth control include abstinence , barrier method , oral contraceptive , injection contraceptive skin absorption contraceptive ) . In opinion investigator , capable willing grant write informed consent cooperate study procedures requirement . Use inhale systemic corticosteroid leukotriene inhibitor within 1 month screening . Treatment Omalizumab ( antiIgE ) within 9 month screen visit Concomitant use monoclonal antibody Respiratory infection within 4 week study Unstable asthma indicated selfreport increase symptom increase betaagonist use previous 2 week . Female subject pregnant , nursing pregnancy plan course study Current smoker ( define smoke within last year ) former smoker history &gt; 5 pack year . Major health problem heart disease , type I II diabetes lung disease asthma . Decisions regard criterion base upon judgment investigator . Previous malignancy . Medication asthma , allergy contraception investigator feel may interfere conduct study ( e.g . monoamine oxidase inhibitor Badrenergic antagonist form ) Known history allergic reaction previous antibody administration . Prior treatment antiinterleukin5 monoclonal antibody , Use investigational drug within 30 day enter study , History noncompliance medical regimen subject consider unreliable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>allergic inflammation</keyword>
	<keyword>interleukin-5</keyword>
</DOC>